<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02978677</url>
  </required_header>
  <id_info>
    <org_study_id>STR-PANAMA-2015</org_study_id>
    <nct_id>NCT02978677</nct_id>
  </id_info>
  <brief_title>Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas</brief_title>
  <acronym>PANAMA</acronym>
  <official_title>Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Cancer Consortium (DKTK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiation Oncology Working Group of the German Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial evaluates the effect of a moderately increased radiation dose in patients with
      atypical (grade II) and anaplastic (grade III) meningioma after incomplete or no surgery.
      Endpoint is recurrence-free survival after 5 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial intends to optimize treatment for grade II and grade III (atypical or anaplastic)
      meningioma. Standard treatment for atypical or anaplastic meningioma is surgery. For grade
      III (anaplastic) meningiomas, post-operative radiotherapy would be performed in all cases
      using standard fractionation schedules to a total dose of ~60 Gy. For grade II (atypical)
      meningiomas, although some small patient datasets support early onset of radiotherapy, the
      standard treatment is still to irradiate if tumours are recurrent or if resection was
      macroscopically incomplete. Total doses of 54 to ~60 Gy are applied using standard
      fractionation schedules.

      A major problem of the treatment of atypical or anaplastic meningioma is that beyond surgery
      and radiotherapy, there are only experimental treatment options and the probability of local
      recurrences is 50-100% within the first 5 years for grade II and grade III meningioma.

      The present trial has been developed to evaluate efficacy of a dose-intensified radiotherapy
      treatment schedule for incompletely or not resected meningioma to a total dose of 68 (grade
      II) or 72 Gy (grade III). To minimize normal tissue toxicity, the boost dose or the complete
      radiotherapy is applied using protons. The expectation is a higher recurrence-free survival
      compared to previous reports on outcome of standard dose (60 Gy) radiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>5 years after start of radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>late toxicity</measure>
    <time_frame>5 years after start of radiotherapy</time_frame>
    <description>CTC-AE 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>5 years after start of radiotherapy</time_frame>
    <description>CTC-AE 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years after start of radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patterns of recurrence using MRI</measure>
    <time_frame>5 years after start of radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life by validated quality of life questionnaires</measure>
    <time_frame>5 years after start of radiotherapy</time_frame>
    <description>EORTC-QLQ-C30, EORTC-QLQ-BN20</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Meningioma</condition>
  <arm_group>
    <arm_group_label>Grade II tumors (macroscopic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy 68 Gy(RBE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grade III tumors (macroscopic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy 72 Gy(RBE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grade II/III tumors (completely resected)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy 60 Gy(RBE)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy 68 Gy(RBE)</intervention_name>
    <description>Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton</description>
    <arm_group_label>Grade II tumors (macroscopic)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy 72 Gy(RBE)</intervention_name>
    <description>Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton and boost 2 to 4 Gy(RBE) proton</description>
    <arm_group_label>Grade III tumors (macroscopic)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy 60 Gy(RBE)</intervention_name>
    <description>Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 10 Gy(RBE) proton</description>
    <arm_group_label>Grade II/III tumors (completely resected)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed atypical (WHO grade II) or anaplastic (WHO grade III)
             meningioma with the indication for radiotherapy

          -  MRI (within 24h post-operative, if not available than with a time interval of ~ 6
             weeks) including contrast-enhanced T1 weighted 3D dataset and PET for evaluation of
             macroscopic tumour (residuum)

          -  Karnofsky Performance Score ≥ 60, ECOG ≤2

          -  For women with childbearing potential, (and men) adequate contraception.

          -  Ability of subject to understand character and individual consequences of the clinical
             trial

          -  Written informed consent (must be available before enrolment in the trial)

        Exclusion Criteria:

          -  refusal of the patients to take part in the study

          -  previous radiotherapy of the brain

          -  several manifestations of the meningioma in different regions of the brain or
             additional spinal manifestations

          -  distant metastases

          -  patients who are not suitable for radiotherapy

          -  known other malignant disease within 5 years before radiotherapy (except tumours that
             likely do not impact prognosis and likely not require treatment interfering with study
             therapy, e.g. in-situ carcinoma of the breast or cervix uteri)

          -  pregnant or lactating women

          -  patients with non-MRI compatible metal implants, pacemaker or non-MRI compatible
             external automatic defibrillators

          -  patients not able to understand character and individual consequences of the clinical
             trial

          -  claustrophobic patients

          -  current participation in another clinical intervention study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mechthild Krause, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Technische Universität Dresden, German Cancer Consortium, Helmholtz-Zentrum Dresden - Rossendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mechthild Krause, Prof.</last_name>
    <phone>+49 351 458 5441</phone>
    <email>mechthild.krause@uniklinikum-dresden.de</email>
  </overall_contact>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>November 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Mechthild Krause</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>brain tumors</keyword>
  <keyword>proton radiotherapy</keyword>
  <keyword>photon radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

